Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Effects of Time Efficient Low-volume Interval Exercise on Cardiometabolic Risk Factors in Individuals With Type 2 Diabetes
Exercise is considered a cornerstone in the prevention and treatment of type 2 diabetes, but few patients exercise according to guidelines. In this study the effect of two time efficient high intensity exercise protocols on glycemic control and other cardiometabolic risk factors are investigated in patients with type 2 diabetes.The investigators assume that glycemic control is improved more by low-volume high intensity interval training than by extremely low-volume sprint interval training.
The world prevalence of diabetes mellitus for 2010 is estimated to 6.4 % of the adult
population, and an increase up to 7.7 % is expected before 2030. 90-95 % individuals with
diabetes have type 2 diabetes (T2D).
The complications of T2D lead to substantially increased risk of hypertension,
cardiovascular disease (CVD) and the development of heart failure. CVD is the most common
cause of death in European adults with diabetes, and the risk of developing CVD is double of
that observed in individuals without diabetes. Lowering HbA1c in type 2 diabetes decreases
the absolute risk of developing CVD by 5-17 %, as well as decreasing all-cause mortality by
6-15 %.
Individuals with T2D are recommended to exercise moderately or vigorously for at least 150
minutes per week. However, the majority of adults fail to meet the guidelines for even the
minimum amount of physical activity, and lack of time is often cited as the main reason.
This research group has previously shown that 4x4 minute high intensity aerobic interval
training (AIT) yields significantly greater response on HbA1c, BMI and diastolic dysfunction
in patients with T2D with duration <10years in contrast to present recommendations. AIT
reduces cardiovascular risk factors more than moderate continuous training in patients with
heart failure and metabolic syndrome. In metabolic syndrome, AIT is superior in enhancing
endothelial function, insulin signaling in fat and skeletal muscle and in reducing blood
glucose. This shows that AIT is a time-efficient and highly effective form of exercise for
both patients with T2D and other patient groups.
Recently, even lower training volumes than made use of in the projects presented above, have
shown indications of improving glycaemic control in T2D. Only two weeks with a total of six
sessions of high intensity training reduces blood glucose significantly in individuals with
T2D. Even shorter intervals of all-out activity (2-7 bouts of 20-30 seconds of supramaximal
ergometer cycling) was shown to improve both aerobic capacity and a number of metabolic and
cardiovascular risk factors after few weeks of training.
However, low-volume high-intensity exercise studies are limited for T2D. The present study
aims to compare the effect of two time saving, high intensity exercise protocols on
cardiovascular risk factors in patients with type 2 diabetes. The investigators assume that
glycemic control is improved more by low-volume high intensity interval training than by
extremely low-volume sprint interval training.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
| Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
| Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
| Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
| Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
| Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
| Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
| Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
| Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
| Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
| Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
| Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
| Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |